Citations

Clear

1055 citation(s) found for "Small, J C".

What Is the Role of Endothelial Cells in Cerebral Blood Flow Dysregulation in Small Vessel Disease?
Benarroch, Eduardo E. , Benarroch, Eduardo

Mayo Clinic

Neurology | July 28, 2026 | Volume: 107 | Issue: 4 | Pages: No page available

10.1212/wnl.0000000000218477 | PMID 42520264 Get It

The Genomic Landscape and Treatment Outcomes Associated with CDKN2A/MTAP Loss in Patients with Non–Small Cell Lung Cancer
Vokes, Natalie I. , Symons, Jessica L. , Rhead, Brooke , Hong, Lingzhi , Shah, Pooja A. , Lai, Zhongwu , Zhu, Zhou , Treviño, Santiago , Iorgulescu, J. Bryan , Wu, Jia , Leventakos, Konstantinos , Zhu, Zhou , Bryan, Julian , Zhang, Jianjun , Gibbons, Don L , Heymach, John V , Stewart, Ross , Iyer, Sonia , Leventakos, Konstantinos , Fragkogianni, Stamatina , Chao, Calvin Y. , Rodon, Jordi , Zhang, Jianjun , Heymach, John V. , Fragkogianni, Stamatina , Vokes, N.

Mayo Clinic

Clinical Cancer Research | July 27, 2026 | Volume: No volume available | Issue: No issue available | Pages: OF1-OF14

10.1158/1078-0432.ccr-26-0771 | PMID 42507545 Get It

Abstract Purpose: Homozygous deletion of the 9p21 locus, containing CDKN2A/B and MTAP [CDKN2A/MTAP deletion (CMdel)], underlies emerging therapeutic strategies, including PRMT5/MAT2A inhibition. The clinicogenomic context and treatment outcome associations of CMdel in non–small cell lung cancer (NSCLC) remain incompletely defined. Experimental Design: We analyzed Tempus Lens records with paired DNA (xT) and RNA (xR) sequencing. After quality filtering (purity ≥40%), 16,947 patients were included in the primary dataset, and 10,996 were included in the validation dataset and stratified by deletion status [CMdel vs. CM wild-type (CMwt)]. IFN status was defined by IFN-kappa (IFNK) expression [log2(TPM + 1)] using the 25th percentile of CMwt as the threshold. Immune composition was inferred by quanTIseq. First-line regimens were grouped as immune checkpoint inhibitor (ICI) monotherapy, ICI chemotherapy, chemotherapy, or tyrosine kinase inhibitors (TKI). Best response and time to next treatment (TTNT) with risk-set adjustment and 18-month truncation were assessed. Results: CMdel occurred in 11.7% (n = 1,991) and 15% (n = 1,676), respectively, and was enriched in mucinous histology, stage IV disease, and never smokers. CMdel was associated with EGFR, TERT, and SMARCA4 alterations, whereas CMwt was associated with RB1, SETD2, and ARID2. More than 50% of CMdel tumors harbored targetable coalterations, enriched in EGFR/ALK/RET and relatively depleted in KRAS. CMdel tumors exhibited lower PD-L1, mutation burden, and immune infiltration. TTNT did not differ by CM status for ICI monotherapy or TKI but was shorter in CMdel for ICI chemotherapy and chemotherapy. Discordant and broad deletions were less common and had weaker TTNT association. IFNK-low expression marked immune-excluded subgroups with worse treatment outcomes. Conclusions: CDKN2A/MTAP loss defines a prevalent, genomically distinct NSCLC subset enriched in actionable drivers. CMdel associates with worse outcomes to ICI/chemotherapy-containing regimens. These findings highlight convergent biology at 9p21 and support biomarker-guided development of PRMT5/MAT2A inhibitors in MTAP-deleted NSCLC.
Diffusion MRI Identifies a Prolonged Pre-WMH Phase in Cerebral Small Vessel Disease
Hu, Mingzhao, Lundt, Emily S. , Kamykowski, Michael G. , Reid, Robert I. , Tm, Therneau, Raghavan, Sheelakumari , Cogswell, Petrice M., Griswold, Michael , Windham, B. Gwen, Petersen, Ronald C. , Graff‐Radford, Jonathan , Vemuri, Prashanthi , Lundt, Emily S , Kamykowski, Michael G , Reid, Robert I , Raghavan, Sheelakumari , Griswold, Michael , Jack, Clifford R , Petersen, Ronald C , Graff-Radford, Jonathan , Vemuri, Prashanthi , Hu, Mingzhao, Cogswell, Petrice M. , Windham, B. Gwen , Jack, Clifford R.

Mayo Clinic

Stroke | July 22, 2026 | Volume: 57 | Issue: 9 | Pages: 2789-2800

10.1161/strokeaha.126.055797 | PMID 42483814 Get It

BACKGROUND: White matter hyperintensities (WMH) are widely used to assess cerebral small vessel disease but reflect late-stage injury. Diffusion magnetic resonance imaging (MRI) biomarkers have been proposed to capture earlier small vessel disease-related microstructural damage but their temporal progression relative to WMH and risk factors associated with progression remain unexplored. METHODS: We identified 2077 participants from the population-based cohort study of the Mayo Clinic Study of Aging in Olmsted County, Minnesota (aged 50–101 years) collected between 05/2005 and 09/2024 with longitudinal neuroimaging. Using multioutput nonlinear mixed-effects models in those with at least 2 fluid-attenuated inversion recovery-MRI and diffusion MRI scans, we characterized the temporal progression of WMH and 4 diffusion MRI biomarkers: fractional anisotropy of the genu of the corpus callosum, peak width of skeletonized mean diffusivity, free water, and Arteriolosclerosis-score, which were automatically estimated. Models incorporated participant-specific time shifts, correlations between biomarkers, and effects of risk factors (sex, education, APOE ε4 status, cardiometabolic conditions). RESULTS: The study population had a mean age of 78 years, 47% were women, 28% were APOE ε4 allele carriers, and 80% were cognitively unimpaired, with an average follow-up of 5.2 years (SD, 4.3 years) for fluid-attenuated inversion recovery-MRI and 4.3 years (SD, 3.9 years) for diffusion MRI. Arteriolosclerosis-score, fractional anisotropy of the genu of the corpus callosum, free water, and peak width of skeletonized mean diffusivity became abnormal in 50% of the study population 16, 12, 10, and 7 years before WMH become abnormal (half-width of CI <1 year), respectively. Global markers (Arteriolosclerosis-score, free water, peak width of skeletonized mean diffusivity, and WMH) were correlated, indicating shared substrates of widespread white matter injury. Fractional anisotropy of the genu of the corpus callosum, a vascular risk microstructural injury biomarker, was weakly coupled with WMH and had an earlier but more linear worsening across adulthood. Cardiometabolic conditions predicted earlier worsening of all biomarkers. Female participants showed earlier WMH, fractional anisotropy of the genu of the corpus callosum, and Arteriolosclerosis-score abnormalities, whereas male participants exhibited earlier peak width of skeletonized mean diffusivity and free water abnormalities. CONCLUSIONS: Diffusion MRI biomarkers were abnormal at least a decade before WMH become abnormal in the population, revealing a prolonged phase of early small vessel disease and highlighting their potential for small vessel disease prevention.
Abstract B049: Discovery of a small-molecule degrader targeting the intracellular immune checkpoint CISH
Tang, Xinyi , Ranatunga, Sujeewa, Ansell, Stephen M., Xie, Hao , Ranatunga, Sujeewa , Ansell, Stephen M.

Mayo Clinic

Clinical Cancer Research | July 21, 2026 | Volume: 32 | Issue: 14_Supplement | Pages: B049-B049

10.1158/1557-3265.d32026-b049 Get It

Abstract Introduction and Purpose: Immune checkpoint signaling represents a major barrier to effective antitumor immunity by suppressing cytotoxic T-cell activity. Cytokine-inducible SH2-containing protein (CISH) is a genetically validated intracellular immune checkpoint that constrains cytotoxic T-cell and natural killer cell signaling. Emerging evidence supports a critical, T cell-intrinsic role for CISH in lymphoma. Despite strong biological validation, CISH targeting has thus far been limited to genetic manipulation in adoptive cell therapies. We sought to establish CISH as a drug-tractable target by discovering a first-in-class, cell-permeable small-molecule CISH inhibitor/degrader suitable for scalable immunotherapy development. Methods: CISH biology was characterized using datasets of patients with B-cell lymphoma and isogenic cellular models to define target-dependence benchmarks. Structure-guided small-molecule discovery was enabled through homology modeling and AlphaFold-based predictions of CISH structure. A focused library of covalent CISH binders was synthesized using systematic variation of SH2-engaging motifs and electrophilic warheads. Compounds were evaluated using biophysical binding assays, mass spectrometry–based covalent engagement, cellular degradation, and signaling readouts. Results: Cellular indexing of transcriptomes and epitopes by sequencing (CITE-seq) analysis identified CISH as one of the most highly expressed genes in intratumoral T cells associated with a poor prognosis in patients with non-Hodgkin lymphoma, supporting disease relevance and target enrichment. Genetic ablation or knockdown of CISH in a T cell model (KARPAS299) induced reproducible, target-dependent phenotypes, including enhanced S-phase entry and augmented STAT5 phosphorylation following IL-2 stimulation, establishing rigorous cellular benchmarks for pharmacologic modulation. We designed and synthesized over 50 candidate CISH binders incorporating covalent SH2-domain engagement. Multiple compounds showed direct binding to CISH by thermal shift analysis and selective covalent modification at Cys144 by mass spectrometry. Introduction of a masked phosphate motif significantly improved intracellular exposure, confirmed using a BODIPY-labeled analog. Lead compounds demonstrated target engagement by cellular thermal shift assay and induced rapid, concentration-dependent degradation of endogenous CISH within 4 hours in cells, while maintaining high selectivity over related SOCS family members, demonstrating both target engagement and specificity. Conclusions: This work establishes CISH as a chemically tractable intracellular immune checkpoint and reports the discovery of the first selective, cell-permeable small-molecule CISH degrader. These data provide a strong foundation for further structure activity relationship optimization and position CISH degradation as a promising drug discovery strategy to modulate T cell function and enhance antitumor immunity. Citation Format: Hao Xie, Xinyi Tang, Sujeewa Ranatunga, Stephen M. Ansell. Discovery of a small-molecule degrader targeting the intracellular immune checkpoint CISH [abstract]. In: Proceedings of AACR Drug Discovery and Development (AACR D3) Conference; 2026 Jul 21-24; Boston, MA. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(14_Suppl):Abstract nr B049.
Comparing Regression Adjustment, Matching, and Inverse Probability Weights in Small Sub-Populations in the HIV SUCCESS Consortium: A Real-World Data Example
Kyle, Ryan P. , Heinke, Dominique, Napravnik, Sonia, Chander, Geetanjali, Baiers, Ross , Cachay, Edward, Kipke, Michele, Moore, Richard D., Mayer, Kenneth H., Parra, Luis, Fredericksen, Rob J., Reisner, Sari, Christopoulos, Katerina , Yendewa, George A., Baum, Marianna, Bamford, Laura, Kitahata, Mari M., Saag, Michael S. , Crane, Heidi M. , Whitney, Bridget M. , Baum, Marianna K. , Drumright, Lydia N , Delaney, Joseph A C , Baum, Marianna , Drumright, Lydia N. , Heinke, Dominique, Napravnik, Sonia , Chander, Geetanjali , Lesko, Catherine R. , Mustanski, Brian , Cachay, Edward R. , Kipke, Michele D. , Mayer, Kenneth, Parra, Luis, Reisner, Sari L. , Christopoulos, Katerina A. , Yendewa, George A. , Delaney, Joseph A.

Mayo Clinic

Substance Use: Research and Treatment | July 16, 2026 | Volume: 20 | Issue: No issue available | Pages: No page available

10.1177/29768357261469399 | PMID 42491262 Get It

Objectives To understand the trade-offs between different statistical modeling approaches, using real world data with small sub-populations, with rare exposures and increasingly rare outcomes. In particular, to compare adjusted regression, inverse probability weighting, and matching. Methods Data for these analyses came from the RADAR (N=1,134) and combined CNICS/JHHCC (N=14,434) cohorts. We estimated prevalence ratios (PRs) for self-reported use of specific substances comparing subpopulations (SP), SP-1 vs SP-3 and SP-2 vs SP-3, where SP-1 was the largest proportion (92% in RADAR, 81% in CNICS/JHHCC), SP2 was moderate proportion (18% in CNICS/JHHCC) and SP-3 was the smallest proportion (8% in RADAR, 1% in CNICS/JHHCC) of the population. We calculated PRs using 1) unadjusted relative risk regression (RR); and adjusted estimates controlling for age, race/ethnicity, study site, and year of interview using: 2) standard adjustment in RR; 3) stabilized inverse probability of treatment weighting (IPTW); and 4) matching with up to 3 matches from SP-1 or SP-2 per SP-3 participant. Results For most substances, all methods yielded consistent estimates. There were large weights in some of the IPTW analyses and in three cases these resulted in substantially divergent estimates. For the comparison between SP-1 and SP-3, the estimate for smoking was 1.3-fold greater in the matched analysis (PR=1.33, 95% CI: 1.02-1.75) than in IPTW (PR=1.03, 95% CI: 0.78-1.37 ATE and PR=1.05, 95% CI: 0.88-1.26 ATT). Even more extreme divergence in estimates was observed for differences between SP-2 and SP-3 with respect to methamphetamine/amphetamine, (IPTW-ATE: PR=1.51, 95% CI: 0.79-2.89; IPTW-ATT: PR=2.36, 95% CI: 1.36-4.12); vs Matching: PR=2.71, 95%CI: 1.47-4.99) and cocaine (IPTW-ATE: PR=1.15, 95% CI: 0.55-2.38; IPTW-ATT: PR=1.81, 95% CI: 1.03-3.18); vs Matching: PR=1.38, 95%CI: 0.76-2.53). Conclusion The combination of a rare exposure and a rare outcome can produce challenges for commonly used confounding adjustment strategies, and it is often best to compare different modeling approaches to gain greater insight.
Complete Imaging Resolution of Ductal Carcinoma In Situ During Osimertinib Therapy for Synchronous EGFR Exon 19-Mutant Non-Small Cell Lung Cancer: A Case Report
Sandoval, Letícia , Sharpe, Richard E. , Fullenkamp, Austin J., Downs, Erinn, Mina, Lida A. , Mina, Lida , Downs, Erinn

Mayo Clinic

International Journal of Molecular Sciences | July 3, 2026 | Volume: 27 | Issue: 13 | Pages: 5995

10.3390/ijms27135995 | PMID 42450262 Get It

A 64-year-old Asian woman diagnosed with synchronous breast ductal carcinoma in situ (DCIS) and stage IV EGFR-mutated non-small cell carcinoma of the lung (NSCLC). A decision was made to defer management of the DCIS and initiate Osimertinib for lung cancer treatment, since this was a life-limiting diagnosis. At 9 months, restaging FDG-PET CT showed an interval response in the NSCLC and complete loss of FDG avidity at the biopsy-proven DCIS site. Breast MRI confirmed complete imaging resolution of the DCIS. The clinical resolution of breast DCIS during third-generation EGFR inhibitor therapy has not been previously reported in humans and highlights a potential role for the EGFR/HER2 (ERBB) pathway in pre-invasive breast cancer.
Safety and performance of small bowel capsule endoscopy in patients with surgically altered gastrointestinal anatomy
Naseem, Zehra, Prado, Renan, Aggarwal, Manik, Nasser, Jason, Wu, Yueqi, Yang, Qijun, McMichael, John, Kundu, Rupayan, Funk, Cynthia, Ford, Andrew, Simons-Linares, C. Roberto, Naseem, Zehra , Kaul, Ridhima , Chatterjee, Arjun , Aggarwal, Manik , Yang, Qijun , Kundu, Rupayan , Ford, Andrew M. , Simons-Linares, C. Roberto , Rubio‐Tapia, Alberto

Mayo Clinic

Scandinavian Journal of Gastroenterology | July 2, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-8

10.1080/00365521.2026.2696878 | PMID 42390964 Get It

Current Roles of Neoadjuvant and Perioperative Immunotherapy in Non–Small Cell Lung Cancer
Fankuchen, Olivia , Punekar, Salman R. , Velcheti, Vamsidhar , Punekar, Salman R. , Fankuchen, Olivia

Mayo Clinic

JCO Oncology Practice | June 29, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1200/op-25-01265 | PMID 42372213 Get It

Immune checkpoint inhibitors (ICIs) in non–small cell lung cancer (NSCLC) have improved survival for patients with early-stage NSCLC who are candidates for surgical resection. ICIs enhance antitumor responses and improve a variety of perioperative outcomes when used in the neoadjuvant, adjuvant, or perioperative setting. This review summarizes immunotherapies currently approved for neoadjuvant, adjuvant, and perioperative treatment of resectable NSCLC and the supporting evidence for approval. Gaps in data and future areas of clinical interest of using immunotherapies to maximize survival outcomes are also discussed.
Small Cell and Large Cell Neuroendocrine Carcinoma of the Colon and Rectum: Population-Based Analysis of Incidence, Survival, and Site-Specific Outcomes
Sun, Nora Yanyi , Xiao, Alexander , Hálfdánarson, Þorvarður R. , Hobday, Timothy J., McGarrah, Patrick W. , O'Donnell, C. , Shi, Qian , Sonbol, Mohamad Bassam , Tran, Nguyen H., Jin, Zhaohui , Sun, Nora Y. , Xiao, Alexander H , O'Donnell, Conor D J , Sonbol, Mohamad B , Halfdanarson, Thorvardur R , Shi, Qian , Jin, Zhaohui , McGarrah, Patrick , Hobday, Timothy J. , Tran, Nguyen H.

Mayo Clinic

Cancers | June 18, 2026 | Volume: 18 | Issue: 12 | Pages: 1976

10.3390/cancers18121976 | PMID 42352508 Get It

Background: Colorectal neuroendocrine carcinomas (NECs), including small cell (SCNEC) and large cell (LCNEC) subtypes, are rare but aggressive malignancies with limited population-level data. Moreover, prior studies have limited stratification by histologic subtype and anatomic location, despite evidence of disease heterogeneity in colorectal malignancies. This study aimed to characterize the clinical characteristics, treatment patterns, and outcomes of colorectal NEC by histologic subtype and tumor location, and to compare them with neuroendocrine tumors (NETs) and adenocarcinomas (ACs). Methods: A retrospective cohort review was conducted utilizing the SEER database from 2000 to 2022 to identify patients with colorectal SCNEC, LCNEC, NET, and AC. Demographic, clinical, therapeutic and survival data were analyzed and compared using Kaplan–Meier methods, log-rank tests, and Cox proportional hazards regression. Results: A total of 790 SCNEC, 498 LCNEC, 31,200 NET, and 638,898 AC cases were identified. SCNEC and LCNEC were associated with advanced stage at diagnosis (66% and 55% stage IV, respectively) and inferior survival outcomes compared to NET and AC (median OS (mOS) of 7 and 8 months for SCNEC and LCNEC, respectively, p = 0.0002). Stratified by location, colonic SCNEC had the poorest survival (mOS 5 months), worse than rectal SCNEC (mOS 9 months); this pattern was not observed in LCNEC. Surgical resection was associated with improved OS in both NEC subtypes (HR range 0.25–0.56, all p < 0.012). Radiation therapy was associated with improved survival in NEC overall (SCNEC HR 0.58; LCNEC HR 0.71, both p < 0.05), with the observed benefit appearing greatest in rectal NEC. Demographic factors were associated with survival in NET and AC but had no significant impact in NEC. Conclusions: Colorectal SCNEC and LCNEC are highly aggressive malignancies with poor outcomes, with SCNEC demonstrating modestly inferior outcomes compared to LCNEC. This study demonstrates that both histologic subtype and anatomic site of disease are important determinants of prognosis and treatment response. This supports the concept that colorectal NEC represents a biologically heterogeneous disease, with colonic SCNEC showing the worst outcomes and rectal NEC associated with a potential enhanced response to radiation. These findings support the need for further prospective and molecular studies to better define treatment approaches and targeted therapies for these rare malignancies.
Risk Factors for Small-Bowel Crohn’s Disease Recurrence After Total Proctocolectomy
Mirande, Maxwell D. , Flaherty, E V, Reynolds, Ian, Alaoui, Ahmed A., Peña, Danilo Tueme de la, Jakubaukas, Matas, Mishra, Nitin, Stochhi, Luca, Perry, William , Mathis, Kellie L., Reynolds, Ian S. , Alaoui, Ahmed Amine , Ore, Ana Sofia , Flaherty, Emily G, Alaoui, Ahmed A , Tueme de la Pena, Danilo, Jakubauskas, Matas, McKenna, Nicholas P , Perry, William R , Reynolds, Ian S , Jakubauskas, Matas , Stocchi, Luca , Mathis, Kellie L. , McKenna, Nicholas P.

Mayo Clinic

Diseases of the Colon & Rectum | June 12, 2026 | Volume: 69 | Issue: 9 | Pages: 2266-2272

10.1097/dcr.0000000000004329 | PMID 42283278 Get It

BACKGROUND: Surgical management of Crohn’s disease of the colon and rectum frequently requires total proctocolectomy with end ileostomy. There are limited data on the need for Crohn’s disease–directed therapy and the prevalence of recurrence after surgery. OBJECTIVE: To determine the risk of small-bowel Crohn’s disease recurrence and evaluate risk factors for postoperative recurrence after total proctocolectomy with end ileostomy. DESIGN: Retrospective cohort study. SETTINGS: Multistate tertiary health care system. PATIENTS: Adult patients with Crohn’s disease undergoing total proctocolectomy with end ileostomy between 2014 and 2023. MAIN OUTCOME MEASURES: The primary outcome was small-bowel Crohn’s disease recurrence. RESULTS: A total of 193 patients with a median age of 45 years (interquartile range, 34–61) were included. More than half of the patients (n = 102; 52.9%) had a history of small-bowel Crohn’s disease, and the majority (n = 134; 69.4%) received biologic therapy before surgery. The median follow-up time was 4.8 years (interquartile range, 2.0–7.6). Postoperatively, 30.6% of patients (n = 59) received biologic therapy. Thirty-five patients (18.1%) had small-bowel Crohn’s disease recurrence for an estimated 5-year recurrence-free rate of 80.2% (95% CI, 73.0–85.7). Seven patients (3.6%) developed small-bowel Crohn’s disease recurrence requiring surgery for an estimated 5-year surgical recurrence-free rate of 94.7% (95% CI, 89.0–97.5). On multivariable analysis, history of small-bowel Crohn’s disease (HR 2.17; 95% CI‚ 1.04–4.54) and diagnosis at age younger than 18 years (HR 2.31; 95% CI‚1.1–4.86) were associated with small-bowel Crohn’s disease recurrence. LIMITATIONS: Retrospective design and nonstandardized follow-up. CONCLUSIONS: Patients undergoing total proctocolectomy with end ileostomy for Crohn’s disease have approximately a 20% risk of small-bowel recurrence at 5 years but a low risk of requiring surgical intervention. Patients with a history of small-bowel Crohn’s disease and younger age at diagnosis have a higher risk of recurrence and may warrant consideration of more frequent surveillance and medical prophylaxis. See Video Abstract . FACTORES DE RIESGO DE RECURRENCIA DE LA ENFERMEDAD DE CROHN DEL INTESTINO DELGADO DESPUÉS DE UNA PROCTOCOLECTOMÍA TOTAL ANTECEDENTES: El tratamiento quirúrgico de la enfermedad de Crohn del colon y el recto frecuentemente requiere proctocolectomía total con ileostomía terminal. Existe información limitada sobre la necesidad de terapia dirigida a la enfermedad de Crohn y la prevalencia de recurrencia tras la cirugía. OBJETIVO: Determinar el riesgo de recurrencia de la enfermedad de Crohn del intestino delgado y evaluar los factores de riesgo de recurrencia posoperatoria tras proctocolectomía total con ileostomía terminal. DISEÑO: Estudio de cohorte retrospectivo. ÁMBITO: Sistema de atención médica terciaria multiestatal. PACIENTES: Pacientes adultos con enfermedad de Crohn sometidos a proctocolectomía total con ileostomía terminal entre 2014 y 2023. PRINCIPALES MEDIDAS DE RESULTADO: El resultado primario fue la recurrencia de la enfermedad de Crohn del intestino delgado. RESULTADOS: Se incluyeron un total de 193 pacientes con una mediana de edad de 45 años (RIC, 34-61). Más de la mitad de los pacientes (n = 102, 52,9 %) tenían antecedentes de enfermedad de Crohn del intestino delgado y la mayoría (n = 134, 69,4 %) recibieron terapia biológica antes de la cirugía. El tiempo medio de seguimiento fue de 4,8 años (RIC, 2,0-7,6). Después de la cirugía, el 30,6 % de los pacientes (n = 59) recibieron terapia biológica. Treinta y cinco pacientes (18,1 %) tuvieron recurrencia de la enfermedad de Crohn del intestino delgado para una tasa estimada libre de recurrencia a 5 años del 80,2 % (IC del 95 %, 73,0-85,7). Siete pacientes (3,6 %) desarrollaron recurrencia de la enfermedad de Crohn del intestino delgado que requirió cirugía para una tasa estimada libre de recurrencia quirúrgica a 5 años del 94,7 % (IC del 95 %, 89,0-97,5). En el análisis multivariable, los antecedentes de enfermedad de Crohn del intestino delgado (HR 2,17; IC del 95%: 1,04-4,54) y el diagnóstico antes de los 18 años (HR 2,31; IC del 95%: 1,1-4,86) se asociaron con la recurrencia de la enfermedad de Crohn del intestino delgado. LIMITACIONES: Diseño retrospectivo y seguimiento no estandarizado. CONCLUSIONES: Los pacientes sometidos a proctocolectomía total con ileostomía terminal por enfermedad de Crohn tienen aproximadamente un 20% de riesgo de recurrencia en el intestino delgado a los 5 años, pero un bajo riesgo de requerir intervención quirúrgica. Los pacientes con antecedentes de enfermedad de Crohn del intestino delgado y menor edad al diagnóstico tienen un mayor riesgo de recurrencia y podrían requerir una vigilancia más frecuente y profilaxis médica. (AI-generated translation )